BioRx Receives Limited Distribution Rights to Corifact® for the Treatment of Congenital Factor XIII Deficiency

Cincinnati, OHIO - July 11, 2012 – BioRx, a national specialty pharmacy and infusion services provider, has been added to the limited distribution network for Corifact® [Factor XIII Concentrate (Human)], manufactured by CSL Behring. Corifact is the only FDA-approved treatment for congenital Factor XIII (FXIII) deficiency, reported to be one of the rarest bleeding disorders in the […]